PNC Financial Services Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

PNC Financial Services Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468	Buy	24 +12	+100%	+$218	﹤0.01%	5000
2026 Q1	$224	Sell	12 -35	-74%	-$580	﹤0.01%	5021
2025 Q4	$620	Sell	47 -12	-20%	-$142	﹤0.01%	4792
2025 Q3	$424	Sell	59 -4,281	-99%	-$223K	﹤0.01%	4837
2025 Q2	$205K	Sell	4,340 -4,860	-53%	-$198K	﹤0.01%	2187
2025 Q1	$359K	Buy	9,200 +700	+8%	+$30.2K	﹤0.01%	1764
2024 Q4	$460K	Buy	8,500 +320	+4%	+$16.3K	﹤0.01%	1600
2024 Q3	$412K	Buy	8,180 +44	+0.5%	+$2.06K	﹤0.01%	1675
2024 Q2	$358K	Buy	8,136 +1,322	+19%	+$56K	﹤0.01%	1730
2024 Q1	$342K	Buy	6,814 +667	+11%	+$36.2K	﹤0.01%	1792
2023 Q4	$371K	Buy	6,147 +2,067	+51%	+$107K	﹤0.01%	1699
2023 Q3	$233K	Sell	4,080 -247	-6%	-$13.6K	﹤0.01%	2009
2023 Q2	$221K	Buy	+4,327	New	+$116K	﹤0.01%	2127

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PNC Financial Services Group's MLTX Position: Q2 2026 in Review

PNC Financial Services Group increased its MoonLake Immunotherapeutics (MLTX) stake by 100% in Q2 2026, buying an estimated $218 and bringing the position to 24 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #5000.

PNC Financial Services Group first reported a position in MLTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $460K in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

PNC Financial Services Group held 24 shares of MoonLake Immunotherapeutics worth $468 as of Q2 2026.
PNC Financial Services Group bought 12 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $218.
MoonLake Immunotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5000 holding.
PNC Financial Services Group first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 13 quarters since.
PNC Financial Services Group's MoonLake Immunotherapeutics position peaked at $460K in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.